Tudor Financial Inc. Purchases New Shares in Amgen Inc. (NASDAQ:AMGN)

Tudor Financial Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,183 shares of the medical research company's stock, valued at approximately $3,281,000. Amgen makes up approximately 2.0% of Tudor Financial Inc.'s holdings, making the stock its 9th biggest holding.

A number of other institutional investors have also made changes to their positions in the business. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter valued at $25,000. Strategic Financial Concepts LLC bought a new position in Amgen in the second quarter valued at about $26,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the third quarter worth about $29,000. Hershey Financial Advisers LLC bought a new stake in Amgen during the 2nd quarter worth about $30,000. Finally, nVerses Capital LLC acquired a new position in Amgen during the 2nd quarter valued at about $31,000. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the subject of several analyst reports. Dbs Bank upgraded shares of Amgen to a "strong-buy" rating in a research report on Monday, September 16th. Jefferies Financial Group reiterated a "buy" rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. TD Cowen raised their price target on Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Bank of America reiterated an "underperform" rating and issued a $256.00 price objective on shares of Amgen in a report on Tuesday. Finally, William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $319.68.

Amgen Stock Performance

Shares of AMGN traded up $0.65 during midday trading on Thursday, reaching $274.06. The stock had a trading volume of 3,474,019 shares, compared to its average volume of 2,614,881. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a 50 day simple moving average of $303.87 and a 200-day simple moving average of $315.16. The firm has a market cap of $147.32 billion, a PE ratio of 35.21, a P/E/G ratio of 3.02 and a beta of 0.55. Amgen Inc. has a one year low of $257.80 and a one year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the business earned $4.96 earnings per share. The business's revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.47%. Amgen's dividend payout ratio (DPR) is 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.